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818ABSTRACTThe incidence of Crohn disease (CD) has been increasing and surgery needs to
be contemplated in a substantial number of cases. The relevant advent of
biological treatment has changed but not eliminated the need for surgery in
many patients. Despite previous publications on the indications for surgery in
CD, there was a need for a comprehensive review of existing evidence on the
role of elective surgery and options in pediatric patients affected with CD. We
present an expert opinion and critical review of the literature to provide
evidence-based guidance to manage these patients. Indications, surgical
options, risk factors, and medications in pre- and perioperative period are
reviewed in the light of available evidence. Risks and benefits of surgical
options are addressed. An algorithm is proposed for the management of
postsurgery monitoring, timing for follow-up endoscopy, and treatment options.
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he incidence of pediatric Crohn disease (CD), particularly in
children 10 to 19 years of age, is increasing and the phenotypeT
is often characterized by extensive inflammation and an aggressive
and progressive disease course including growth failure (1–6).
Despite optimized treatment, almost one-third of the patients will
have complications such as fistulae, strictures, and abscesses, under-
going invasive treatment within 5 years of diagnosis (7,8). Further-
more, the risk of having surgery is several times higher in children
with a long-standing disease than in adults. The risk of surgery at the
age of 30 for patients with onset of CD in childhood is 48 5%
compared with 14 2% for patients with adult-onset CD (9).
Surgical procedures in patients with CD can be categorized
into 3 major groups: ileocecal resections performed to achieve
remission, treatment of complications such as fistulae with or
without abscess formation and strictures, and salvage proceduresSPGHAN. All rights reserved.
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tory colitis or small bowel resection for refractory jejuno/ileitis
(10). Urgent surgical procedures related to peritonitis or abdominal
abcesses are beyond the scope of this document and will not
be addressed.
The most recent pediatric European Crohn’s and Colitis
Organization (ECCO)/European Society for Pediatric Gastroenter-
ology, Hepatology, and Nutrition (ESPGHAN) guidelines provide
guidance for medical, but not for surgical treatment of CD (11). The
role of surgery in children with CD, especially with respect to
elective resection of medically resistant localized disease, has been
addressed in the 1st and the 2nd European evidence-based con-
sensus guidelines (12,13). The present report is based on expert
opinion and a critical review of the literature and is intended to
provide evidence-based guidance for surgical management of
pediatric patients with CD, including the role of elective surgery
in not only achieving and maintaining remission, but also treating
complications and managing pre- and postoperative care. The
objectives are to clarify indications as well as delineate risks and
benefits of surgery taking into consideration the needs of the
individual patient, the natural history of the disease, and currently
available alternative medical treatment options.
METHODOLOGY
Selection of the Authors and the Relevant
Clinical Topics
The development of these guidelines was initiated at the
annual meeting of the ESPGHAN IBD Working Group in Porto in
the year 2013, and was followed by an open call to Working Group
members. To obtain a balanced position, several other experts
joined, including pediatric surgeons. Five major topics were
addressed by independent working groups:a. I
b. Cwwndications for surgery in pediatric CD
onsideration for and type of surgeryc. Pre- and postoperative cared. Risks associated with surgery as it relates to the natural history
of disease
Surgical management of perianal diseasee.Literature Search, Grading of the Evidence,
Consensus StrategyThe authors of the Working groups performed a systematic
literature search using MEDLINE-Pubmed, Embase, CINAHL, and
the Cochrane Library with the last search date of 2015. Because
evidence-based reports on surgical procedures in children with CD
are limited, the review included data in adults. The limited pediatric
literature precluded the use of the Oxford grading.
Proposed recommendations and practice points were dis-
cussed during the 2 face-to-face meetings and anonymous voting.
Where the pediatric literature was sparse, recommendations were
based on adult data. Controversial issues or recommendations in the
absence of relevant pediatric data were resolved by consensus. Final
recommendations were accepted when at least 80% agreement
was achieved.
EPIDEMIOLOGY OF SURGERY FOR PEDIATRIC
CROHN DISEASE
The natural history of pediatric CD, including need for
surgery, is based mainly on cohort studies. Early case series and
cohorts from the 1970s and 1980s reflected the lack of effective
medications in pediatric-onset inflammatory bowel disease (IBD) to
maintain remission (14,15). Copyright © ESPGHAN and NA
w.jpgn.orgAs a result of the increasing use of immunomodulators and
biological anti-tumor necrosis factor (TNF)a agents, such as inflix-
imab (IFX) and adalimumab (ADA) introduced during the past 15
years to both induce and maintain remission in chronically active
CD, the rate of surgical management of pediatric CD may have
changed. In pediatric clinical practice, the availability of anti-TNFa
agents has differed among regions and countries. These medications
approved rapidly in North America (16) and parts of Europe (eg,
Denmark (17), the Netherlands (18), and France (19)) as they were
able to use adult data to prescribe them. In the United Kingdom, for
example, evidence from randomized controlled trials (RCTs) in
children (20–22) were required before approval was given, and in
much of eastern Europe availability of anti-TNF agents to treat
children with CD came much later. For these reasons, the natural
history is evolving, with systematic reviews showing reduced
surgical rates in adult CD with increased use of thiopurines and
IFX (23,24). In contrast, limited evidence in pediatric CD from
either case series or population-based cohort studies suggest lower
surgical rates when 25% of patients receive anti-TNFa medications
for CD versus earlier periods in the same region when patients were
not treated with these medications (19,25,26). The level of exposure
to immunomodulators and anti-TNFa agents during the period of
assessment is critical in determining its impact on natural history of
CD. Finally, when looking for evidence to evaluate the risk of
surgical resection or postresection recurrence in children with CD,
most information is obtained from series of primarily adult patients
that include small numbers of pediatric patients with CD (27,28).
As case series of surgery for pediatric CD have been pub-
lished primarily from single academic centers, rather than popu-
lation-based cohorts, there is a possibility of bias based upon
referral, increased severity of CD, or more access to anti-TNFa
therapy (14,15,19,25,26,29–31). Although longitudinal pediatric
CD data from Europe and Canada suggest decreasing rates of CD
surgery with time, the reverse has been described in the United
States (8,25,32,33). When pediatric-onset CD was compared with
adult-onset CD in the same Scottish population, the rate of surgery
at 10 years follow-up and median time to first surgical resection
were lower (35% vs 56%) and longer (13.7 vs 7.8 years), respect-
ively (34). Recent reports show that recurrence rate seems to be high
in children: for example, the French Registry of Inflammatory
Bowel Diseases incident cohort from Northern France reported
CD resection rates of 7% of pediatric patients at 1 year, 20% at 3
years and 34% at 5 years (8). Further follow-up of the 404 pediatric
CD cases diagnosed between 1988 and 2004 in the French Registry
of Inflammatory Bowel Diseases cohort noted a recurrence rate of
29% in 140 patients 10 years after their first resection (35).
Smoking, prior resections, perianal disease, penetrating disease
behavior and extensive (>50 cm) small bowel resection have been
identified as risk factors for postoperative recurrence in mainly
adult-onset CD. The relevance of serology and CD genotype are not
known, and there are no unequivocal, confirmed risk factors for
post-operative recurrence in the current pediatric literature (27), but
stricturing and penetrating CD at diagnosis are associated with an
increased risk for a second resection (36).
CONSIDERATIONS FOR SURGERY IN PEDIATRIC
CROHN DISEASE
Definition of a Refractory Crohn Disease
Patient
A patient is considered to be refractory to given treatment
options when his/her signs and symptoms are caused by CD, relapse
during optimized maintenance therapy (immunomodulators, anti-
TNFa agents or other biologicals released for pediatric CD) and do
not sufficiently respond to induction therapy (corticosteroids,SPGHAN. All rights reserved.
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TABLE 1. Issues to consider before surgical intervention
Item Features to consider
CD phenotype Paris classification: distribution, structuring or
inflammatory or both, presence and location of
fistula
Disease severity Affected bowel segments
In case of strictures Length, degree, and particular location of the
stricture (eg, a short stricture in the proximal
duodenum versus the same stricture in the
small or large bowel)
In case of fistula 1 or multiple, location (starting and ending point)
Current drug
treatment
Compliance? Previous and current response? Do
they increase the risk of complications and
should be discontinued or decreased?
Previous drug
treatment
Reason for discontinuation: Loss of response?
Nonadherence? Side-effects?
Previous EEN Compliance, response and duration of remission
Growth potential Age, pubertal status, bone age, height for age,
and growth velocity over the last 6 (12)
months
Nutritional status BMI, deficiencies of micronutrients affecting the
immune system and healing process





BMI¼ bone mass index; CD¼Crohn disease; EEN¼ exclusive enteral
nutrition; P-IBD¼ pediatric-onset IBD.
Amil-Dias et al JPGN  Volume 64, Number 5, May 2017Exclusive Enteral Nutrition—EEN) in spite of being on mainten-
ance therapy. Nonadherence, insufficient therapy, and other causes
for the signs and symptoms should be excluded before surgery
is considered.
It is mandatory to prove with a high degree of certainty that
signs and symptoms are due to active CD and not due to other
causes (eg, diarrhea due to bile salt loss or infection, abdominal pain
due to functional disorders or depression, growth failure due to
growth hormone or nutritional deficiencies). Alternatively, if a
specific bowel segment is responsible for symptoms, surgical
intervention may be more appropriate than continued medical
treatment. Nonadherence, inadequate dosing, or duration of medical
therapy must be considered, before the patient is deemed to be
refractory to therapy. Some relevant issues that should be con-
sidered before surgical intervention are shown in Table 1.
The decision for or against elective surgery in a patient with
refractory CD rests on the short-term and long-term risks and
benefits, such as the extent of disease and likelihood of remission
or recurrence with resection. The decision is highly individualized.
Surgical resection is not curative for CD. Relapse, both at the
area of anastomosis and at other sites, frequently occurs within 5
years postsurgery (31,37,38). Refractory disease implies that the
defined treatment goal for this patient cannot be achieved with the
nonsurgical treatment option(s) and/or that continued medical
management may have higher short-term or long-term risks than
surgery. One must also take into account the relative costs and
potential toxicities of long-term medical therapy. Treatment goals
differ from patient to patient and should be well defined when a
surgical procedure is considered. They include improvement of
signs and symptoms severely affecting the quality of life (eg, pain,
diarrhea, obstruction, fecal incontinence, growth failure) or pre-
vention of severe complications (eg, ileus in bowel occlusion,
fistula, abscess formation).
Indications for Surgery
Statement 1. Surgery may be considered as an alternative
to medical therapy when a patient has active disease
limited to a short segment(s) despite optimized medical
treatment. (Agreement 100%)
Statement 2. Surgery should be considered in children in
prepubertal or pubertal stage if growth velocity for bone
age is reduced over a period of 6 to 12 months in spite of




82n the absence of refractory disease, elective surgery is usually
ot indicated.
In prepubertal or pubertal children with a delay in bone age,2.
resection of a localized disease segment that is resistant to
conservative therapy, may lead to catch-up growth within the
next 6 months of postoperative period.Growth failure is more frequent in CD than in ulcerative
colitis (UC) being present in 15% to 40% of pediatric CD patients
(39,40). Although the use of corticosteroids has been implicated in
growth failure, uncontrolled disease activity is considered the major
factor. One of the main contributors to growth impairment is
malnutrition influenced by enteric losses with malabsorption, sub-
optimal intake and increased energy needs (41). Moreover, Copyright © ESPGHAN and NA
0
increased cytokine production [eg, interleukine (IL)-1b, IL-6,
TNFa], impairs hepatic expression of insulin-like growth factor
1 and contributes to growth hormone resistance in chondrocytes.
Growth failure, characterized by delayed skeletal maturation and
delayed onset of puberty, is best described in terms of height-for-
age standard deviation score (z score) or by variations in growth
velocity for a period of 6 to 12 months. Earlier literature described
the role of surgery in promoting growth in CD pediatric patients
(42,43). Most of these studies, however, were performed before the
era of biological agents and may have been impacted by the
increased use of corticosteroids.
Three retrospective trials with growth as an outcome measure
were identified. One of these evaluated the effect of surgery on
growth in children with CD who did not respond to medical therapy
(30). Growth and nutritional status improved by 6 and 12 months
after surgery, with a significant increase in weight and height z
scores. The other 2 studies analyzed the postoperative course of
pediatric CD and the predictive factors of early postoperative
recurrence (44,45). After surgery, a significant improvement
occurred in z scores for height and a mean height velocity of
patients increased from 2.3 cm/y preoperatively to 3.4 cm/y follow-
ing surgery. These results were supported by other studies (46–49).
Moreover, delaying surgical intervention into the late stages of
puberty results in poor catch-up growth (39).
Furthermore, concerns about inadequate growth and the
prospect of not achieving adult growth potential may impact the
quality of life for some patients. For these reasons, surgery should
be considered a therapeutic strategy for inducing remission in early
or mid-puberty in a child with localized CD who is refractory to
medical therapies. Refusal, intolerance, or increased risks of main-
tenance medications such as immunomodulators or anti-TNFa
agents may also be considered as possible indications for elective
surgery.SPGHAN. All rights reserved.
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Statement 3. A complete assessment of the patient’s gen-
eral and bowel condition is recommended before elective
surgery to optimize the surgical approach, minimize the
length of bowel resection, and reduce the risk of compli-
cations. It should include history, physical examination,
ileocolonoscopy, imaging studies, screening for concomi-




wwhe optimal timing of surgery, the approach (laparoscopic or
pen) and bowel segments to be addressed should be discussed
among the pediatric gastroenterologist, pediatric (or adult)
surgeon, patient, and parents.
It is preferable that ileocolonoscopy (eosophagogastroduode-2.
noscopy being optional depending on the actual disease) and
imaging studies are performed in the center where the surgery
will be performed.
The nutritional status should be assessed by anthropometry,3.
laboratory parameters such as albumin, iron status, and selected
vitamins and trace elements, depending on the individual
patient.
In severe cases an extensive workup for immunodeficiency4.
disorders should be completed in a specialized center before
surgery.SELECTION OF THE TYPE OF SURGERY
Statement 4. Limited resection should be performed when
a patient has localized small bowel or colonic CD not
responsive to medical therapy. (Agreement 100%)
Statement 5. Stricturoplasty needs to be considered when
a symptomatic patient has multiple short strictures in the
small bowel. (Agreement 100%)
Statement 6. Extensive resections of the small bowel
should be avoided as they pose a long-term risk of devel-
opment of short-bowel syndrome. (Agreement 100%)
Statement 7. When a patient has pancolonic disease the
choice of surgery is subtotal colectomy and ileostomy.
Later ileorectal anastomosis can be performed if rectum
is spared and there is no significant perianal disease. One
stage ileo-rectal anastomosis is generally not advised.
(Agreement 100%)
Statement 8. Ileal pouch-anal anastomosis is not recom-
mended when a patient has CD. (Agreement 100%)
Practice points:1. L
2. Aimited resections are especially relevant for ileocecal lesions.
lthough stoma is recommended as a general rule, partial
colectomy and ileo-rectal anastomosis may be performed without
diverting ileostomy as a primary procedure in patients without
significant immunosuppression or malnutrition. Increased rates
of leakage associated with ileo-rectal anastomoses, however,
support the use of temporary diverting ileostomy (44).
Reversal of the diverting ileostomy following colonic3.
resection may result in recurrence of inflammation in the
colon or rectum. Copyright © ESPGHAN and NA
w.jpgn.org4. P
i
SPatients requiring emergent colectomy are not candidates for
mmediate reconstruction and should undergo a 2- or 3-staged
procedure.
Although not recommended as a standard procedure, ileal pouch5.
anal anastomosis may be considered in highly selected cases, that
is, these patients need to be highly motivated and have no perianal
or small bowel disease and good sphincter function. Successful
outcomes can be achieved with this procedure.
Patients and their families should be aware of all possible risks6.
and high complication rate including anastomotic leaks,
anastomotic strictures, fistula formation to the anastomosis,
as well as the risk of recurrence. Significant time should be
dedicated to patients and their families during the counseling
before the surgical procedure to discuss the possible
complications and functional impairment.Limited Small Bowel Disease
For single site disease, such as the ileocecal area, a limited
resection may be the treatment of choice. Reports of isolated small
bowel resection surgery can be found in many of the larger
published pediatric surgical series (1 case each described by Romeo
et al (50), Simon et al (51) and 2 cases each by Ba’ath (52),
Blackburn et al (31), 11 cases by Hansen et al (38), 16 cases by
Diamond et al (29)). There is considerable debate in the literature
whether surgery for CD should be performed laparoscopically or
through the conventional open technique (53–55). The laparo-
scopic surgical approaches, however, can certainly be used safely
in children with low complication rates (29,55–57).
For single and multiple site disease, stricturoplasty is best
undertaken to preserve bowel length. Stricturoplasty has the
advantage of bowel preservation, whereas surgical resection may
put the patient at risk for short bowel. There does not appear to be a
significant difference between the outcomes or the complication
rates between surgical resection or stricturoplasty in pediatric CD
(50).
Standard Heinecke-Miculicz stricturoplasty is suitable for
short segment strictures. Finney type stricturoplasty is used for
strictures up to 20 cm long. For longer than 20 cm strictures, either a
specialized form of stricturoplasty or a combination of resection and
stricturoplasty type with anastomosis may be used.
Colonic Crohn Disease
Symptoms of colitis are typically the first manifestations of
CD in children under the age of 8 years (58,59). The distribution of
the disease may change with age making the choice of most
appropriate surgery more difficult (59). There is a lack of reliable
pediatric data related to the management of Crohn colitis.
The main problem in the choice of operative treatment for
colonic CD is the expected high rate of disease relapse (37,44). Due
to the high incidence of complications and relapses, risk of pediatric
patients with colonic disease to end up with permanent ileostomy
has been considerable. Recent reports in adults suggest that bowel
sparing surgery in the form of segmental resections has better long-
term outcomes (60,61). Segmental large bowel resections have also
been performed in children with left-sided colitis (62) but recent
data in 81 patients suggested that most patients will eventually
require subsequent colectomy (Ian Sugarman, personal communi-
cation). Harper showed that temporary ileostomy is a safe con-
servative procedure which enables improvement in severely ill and
even malnourished patients with Crohn colitis (63). When a sub-
sequent resection becomes necessary, it may be less extensive thanGHAN. All rights reserved.
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improved nutrition (64). Long-term remission is more common in
patients with no significant anorectal disease (65). Female gender
and history of perianal disease have been reported to be predictive
of repeat resection (61). An important technical detail is to perform
a wide bowel anastomosis, preferably with a stapled functional end-
to-end technique that is associated with longer recurrence-free
periods when compared with hand sewn anastomoses (66).
In children with refractory pan-colonic disease the choice of
operation is usually total colectomy and ileo-rectal anastomosis.
Elective resection with a primary anastomosis may be considered in
a stable patient with good nutritional status. In the case of an
emergency the best choice is, however, usually a staged procedure.
Patients undergoing ileo-rectal anastomosis have excellent chances
to avoid protectomy and permanent stoma formation. Preservation
of the ileo-rectal anastomosis despite frequent recurrences of active
disease has been reported in 76% to 86% of the cases (67,68).
Active anorectal disease at the time of the anastomosis is the best
predictor for failure of the anastomosis (68).
An alternative for total colectomy and ileo-rectal anastomo-
sis is ileal pouch-rectal anastomosis. This may be considered in
cases in which only a short segment of the rectum is retained
following resection of diseased large bowel. A short ileal pouch (8–
10 cm) is anastomosed with the rectal stump. The outcomes after
ileal pouch-rectal anastomosis are similar to those after ileo-rectal
anastomosis (69).
Ileal pouch-anal anastomosis is generally thought to be
contraindicated in CD (70). This is based on data from patients
having undergone ileal pouch-anal anastomosis for presumed UC
who subsequently had a change of diagnosis to CD. The cumulative
frequencies of CD of the ileo-anal pouch originally devised for UC
has ranged between 3% and 13% (71). The diagnosis of CD of the
pouch has been associated with 5-fold increase in risk of pouch
failure compared with patients with ileo-anal pouch without CD
(72,73).
There is, however, recent growing evidence that supports
highly selective use of restorative proctocolectomy with ileal
pouch-anal anastomosis for CD. These patients have isolated
colonic CD and no evidence of ileal or perianal involvement.
In patients with severe rectal and perianal disease, proctect-
omy or enteric diversion are rarely indicated, see section of Perianal
disease. Colonic stricturoplasties, although feasible, are associated
with a higher risk of complications and are therefore seldom used.
RISK FACTORS OF COMPLICATIONS OF
SURGERY AND PERIOPERATIVE MANAGEMENT
Immediate Postoperative Complications
Statement 9. Corticosteroids exposure should be mini-
mized prior surgery to reduce surgery-related compli-
cations such as infections. (Agreement 100%)
Statement 10. Anti-TNFa administration during immedi-
ate perioperative period (see practice point) is discour-
aged, as it is associated with an increased risk of infection.
(Agreement 100%)
Statement 11. Nutritional status should be optimized and
anemia corrected to reduce the risk of postoperative
complications. (Agreement 100%)
Statement 12. A patient should cease smoking before
surgery given the strong association of smoking with
postoperative recurrence. (Agreement 100%) Copyright © ESPGHAN and NA
822Practice points:
1. Risk factors of perioperative complications include poor
nutritional status, anemia, cigarette smoking and perioperativeSPcorticosteroid or anti-TNFa treatment.
Immediate postoperative morbidity ranges from 20% to 30%,2.
in small bowel or ileocolic resection to 50% to 60%, in
subtotal colectomy (29,74,75).
Whenever possible, it is recommended to discontinue3.
corticosteroids before surgery or to lower the dose to at least
0.5 mg/kg or 20 mg, whatever is less to minimize the risk
of complications.
It is advisable to avoid anti-TNF drugs during the4.
perioperative period (optimally 4–6 weeks before and in
high-risk patients continuing anti-TNF postoperatively 1–3
weeks following surgery to minimize the risk of complications
and in the latter group the risk of development of drug
antibodies).
Data on the impact of immunomodulators to the risk of5.
immediate postoperative complications is limited and con-
flicting. Although immunomodulators may be used through-
out the perioperative period if maintenance therapy is
indicated postoperatively, it may be reasonable to discontinue
treatment with immunomodulators at least 1 week before
surgery to reduce the risk for infections.
Stress doses of corticosteroids should be administered if6.
steroids are ongoing or discontinued close to the time of the
surgery, or adrenal suppression is not excluded.
Nutritional status should be optimized before surgery by using7.
enteral nutrition (EN), but for some patients TPN may
be needed.
Bowel cleansing is performed at discretion of the surgeon but8.
not routinely required.
Although infrequent, the presence of hyperglycemia should be9.
excluded, as it is associated with poorer outcomes, including
poor wound healing and increased risk of infection.
Hospitalized children with CD should be assessed for potential10.
risk factors for venous thromboembolism (VTE) including
disease activity, steroid use, central venous access, parenteral
nutrition, hypercoagulable condition, and immobilization.
VTE prevention such as hydration, compression stockings,
and mobilization should be provided to all patients.
Pharmacological thromboprophylaxis may be considered in
the postoperative course, although the absolute risk of VTE in
children appears lower than in adults.
If indicated by family history, common genetic mutations11.
associated with an increased risk of VTE should be
screened preoperatively.The most common short-term postoperative complications of
bowel surgery are anastomotic leak, small bowel obstruction and
ileus, infections, need for ileostomy, wound complications, fistulas,
gastrointestinal bleeding, and VTE. Complication rates seem to be
slightly lower in children than in adults, but vary a lot between
procedures and studies (31,76–78). Cigarette smoking is associated
with an increased risk of postoperative complications in adults
(odds ratio [OR]¼ 1.24 (1.09–1.41) with CD (79). Anemia and
weight loss before surgery are also associated with a worse prog-
nosis (79). Blackburn et al (31) recently reported their 10-year
pediatric experience on risk of complications at a regional pediatric
gastroenterology center. Among the 62 patients, there were 13
(22%) early and 5 (8.6%) late complications following intra-
abdominal surgery. Piekkala et al (37) reported their long-term
surgical outcomes in 36 Finnish children. At least 1 surgicalGHAN. All rights reserved.
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postoperative complication rate was significantly lower in patients
who had an ileal 1/16 (6%) or ileo-cecal resection 13/54 (24%)
compared with hemi- 5/12 (42%) or total colectomy 11/21 (52%). In
this report 10% to 30% of patients required further intervention
mainly for ileus, bleeding, and infection (38).
In children, the absolute risk of VTE is lower than in adults
(80,81). The absolute risks for VTE among children with CD with
and without surgery were calculated to be 111.2 and 121.2/10,000
hospitalizations, respectively (80). There are no published trials for
the efficacy and safety of thromboprophylaxis in children with CD,




In adults, most publications have reported a negative impact
of the preoperative use of5 mg prednisone (or its equivalent) daily
within 14 to 60 days before surgery or 10 mg prednisone (or its
equivalent) for at least 4 weeks before surgery (83,84). In their
prospective follow-up study, Nguyen et al (85) reported an excess of
complications, but not mortality, in patients with corticosteroid use
within 30 days before surgery (adjusted OR (95% confidence
interval [CI])¼ 1.26 (1.12–1.41) for CD. In the long-term registry
of North American patients with Crohn Disease (TREAT) registry
glucocorticoid use was an independent risk factor of serious infec-
tions (OR, 2.21; 95% CI, 1.46–3.34) (86,87). In addition to the
septic concerns, steroid use can lead to the suppression of the
hypothalamus-pituitary-axis and subsequent adrenal insufficiency,
even after shorter periods of therapy (84,88,89). For this reason,
perioperative glucocorticoid replacement therapy may be required.
Wound healing complications, such as, disruption, persistent drai-
nage, dehiscence, or wound failure, are usually associated with
chronic use of corticosteroids at high doses (90).
5 Aminosalicylates
There is a paucity of clinical data for perioperative use of 5
aminosalicylates (5-ASA). Kumar et al (91) suggested to discon-
tinue the drug on the day of surgery. Continuing drugs after surgery
is specific to each patient.
Immunomodulators
There are conflicting reports about the use of immunomodu-
lators preoperatively and most data comes from adult studies (84). In a
retrospective study of 159 CD patients undergoing bowel surgery,
Aberra et al (92) found no increased infectious risk among patients
receiving corticosteroids alone or patients receiving thiopurines with
or without corticosteroids, in comparison to patients receiving neither
medications. Additional reports including >200 adult patients each
identified no increased risk of complications with immunosuppres-
sive therapy at surgery (93,94). Tay et al (95) reported a lower
incidence of septic complications in patients receiving immunomo-
dulators (5.6% vs 25%). In contrast, another study found that
thiopurines were associated with an increased risk of intra-abdominal
septic complications (16% vs 6% without therapy) (96).
Existing data do not suggest a significantly increased risk of
perioperative infections or impaired wound healing with metho-
trexate. Given the lack of data, it may be reasonable to discontinue
methotrexate at least 1 week before surgery in patients with a
history of previous or severe septic complications, and resume if
necessary no sooner than 1 week after surgery or when the wound
has healed (97). Copyright © ESPGHAN and NA
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There are conflicting results whether preoperative use of
biologics increases risk of infectious complications (84). There are
only limited data in children (98). A meta-analysis of the preoperative
use of anti-TNF therapy in adults showed an increased prevalence of
postoperative complications (OR¼ 1.45, 95% CI 1.04–2.02; 13
studies, 2538 patients), as well as for both infectious (OR¼ 1.47,
95% CI 1.08–1.99; 10 studies, 2116 patients) and noninfectious
complications (OR¼ 2.29, 95% CI 1.14–4.61; 3 studies, 729
patients) (99). All included studies are retrospective, patient groups
are heterogeneous, the inclusion criteria and definitions of compli-
cations vary, and confounding effects of concomitant therapies are
not defined. Patients treated with IFX were more likely to be treated
with immunomodulators and steroids. Also, the patients usually had
additional risk factors including adverse surgical outcomes, malnu-
trition, and urgent indications for an operation.
Preoperative Nutrition
Practice point:
Consider initiation of EEN (continuous or bolus if tolerated) for
at least 2 weeks before imaging studies and surgery are
performed. Attenuation of inflammation will improve distinc-
tion between bowel narrowing due to stricturing or inflammatory
processes (100). This will allow the surgeon to plan the best
approach (stricturoplasty or resection and minimize bowel loss).
EEN will also allow reduction of corticosteroids, if given, and
improvement of nutritional status.Enteral support whenever possible is preferable to TPN to
improve nutritional status because it is physiologic, is less costly, and
has less potential for sepsis. A number of studies reported that poor
nutritional status at the time of operation significantly increased the
risk of postoperative complications and intra-abdominal infections in
CD (101–104). Intra-abdominal septic complications were associ-
ated with hypoalbuminemia <3.0 g/dL (101) and the complication
rate was 29% among 124 patients with low serum albumin levels
(<3.1 g/dL) but only 6% among patients with normal albumin levels
(104). Improvement of nutritional status by TPN may contribute to a
reduction of postoperative complications in both adult and pediatric
patients (103,105,106). Anastomotic dehiscence is consistently
associated with a serum albumin levels <3.5 g/dL in elective color-
ectal resections in adults (for review (84)). In a study of 78 patients
with penetrating CD, preoperative management, including nutritional
support and weaning off steroids, allowed ileocecal resection with
low rates of postoperative morbidity (107).
LONG-TERM POSTOPERATIVE
COMPLICATIONS
Statement 13. Vitamin B12 levels (active vitamin B12)
should be routinely monitored in patients who undergo
resection of >20 cm of terminal ileum. (Agreement 100%)
Statement 14. Bile acid malabsorption should be suspected
in patients with persistent diarrhea despite clinical
remission or limited disease activity after ileal resection.
(Agreement 100%)
Statement 15. The patient should be informed that after
surgical resection, the risk of bowel obstruction is
increased (either secondary to recurrent disease or adhe-
sions). (Agreement 100%)SPGHAN. All rights reserved.
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1. The risk of postsurgical functional impairment, although small,
should be discussed before patients undergo intestinal resec-82tion. Bowel function is not often affected by localized small
bowel or ileocecal resection. Subtotal colectomy and ileoanal
anastomosis result in an increased frequency of defecation, but
the functional outcome is good when CD stays in remission.
Ileal resection <20 cm of bowel length is infrequently2.
associated with vitamin B12 deficiency or bile acid malabsorp-
tion. Surgical treatment should aim to preserve bowel length by
using bowel sparing techniques.
Methylmalonic acid may help in detecting early vitamin B123.
deficiency (by itself or with a homocysteine test).
As stated in the ‘‘Selection of the type of surgery’’ section, ileal4.
pouch-anal anastomosis should be avoided in CD. Repeated
episodes of pouchitis are common and pouch failure may occur
in CD patients with a pouch.
There is limited evidence that fertility may be lower in patients5.
with CD and this may be further enhanced by surgery
(108,109).Bowel Function
There are limited data on postsurgical bowel function. Only 1
study with a small number of patients addressed the development of
functional problems after small intestinal resection. Almost all
children with limited ileal resection were continent, as were chil-
dren with partial colectomy but this was based on only 6 children
(37). Meta-analysis that compared segmental versus subtotal/total
colectomy in adults found that more patients were continent after
segmental colectomy (110). There are no pediatric data regarding
bowel function after ileo-rectal anastomosis.
The only large study reporting functional outcomes after
proctocolectomy and ileal pouch anal anastomosis (IPAA) in the
pediatric population included 433 patients (5.1% with UC patients
postoperatively classified as CD) (111). Wound infection and pouch
failure rates were significantly higher in patients with CD. Piekkala
et al (37) reported a small pediatric study in which all patients with
IPAA had experienced pouchitis and eventually, 4 of 8 patients
needed bowel diversion. The latter study is the only study addres-
sing the development of functional problems after small bowel
resection but the study is retrospective with small number of
patients. In adult patients functional results after IPAA are incon-
sistent and meta-analysis found no significant functional differ-
ences between CD and UC patients except for increased urgency
and incontinence in CD patients (112–116). Other studies in adults
reported that patients with proven CD who underwent IPAA
developed CD of the pouch in 40% to 63% of cases during the
5-year postoperative period (117,118).
Vitamin B12 Malabsorption
Resection of the terminal ileum may lead to malabsorption of
vitamin B12. Ahmed and Jenkins (119) reported the effect of small
bowel surgery on vitamin B12 levels in 18 children with variable
ileal resection due to CD for a period of 10 years. None of the
children had low vitamin B12 levels before or after small bowel
surgery suggesting that serum levels are poor indicators for actual
needs. Recently, measurement of active vitamin B12 (transcoba-
lamin-bound) has been adopted (120). A recently published sys-
tematic review in adults with IBD found that ileal resections greater
than 30 cm were associated with vitamin B12 deficiency, whereas Copyright © ESPGHAN and NA
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those patients with <20 cm of resected ileum had normal serum
vitamin B12 (121).
Bile Acid Malabsorption
Approximately 95% of bile acids are re-absorbed in the distal
ileum and although their malabsorption can cause diarrhea, it is
unusual to have steatorrhea with malabsorption of fat-soluble
vitamins resulting in the formation of gallstones and kidney stones
(122,123). One pediatric study found that 23% of patients with CD
had bile acid malabsorption (124). Patients with previous ileal
resections (resected bowel length was 10–30 cm) had significantly
higher serum C4-concentrations (7a-hydroxy-4-cholesten-3-one),
suggesting bile acid malabsorption, than patients with ileal inflam-
mation only (124). Adult studies showed bile acid malabsorption
in 55% to 90% of patients who had terminal ileal resections
(125–127).
Resection of the terminal ileum may lead to diarrhea due to
bile acid malabsorption. When suspected, bile acid malabsorption
may be confirmed indirectly by a short-term empirical treatment
with bile acid-binding drugs, such as cholestyramine or colestipol.
Measurement of serum 7a-hydroxy-4-cholesten-3-one levels in
serum may be helpful to establish a diagnosis when available
(128). Measurement of whole body retention of a radioactive
bile acid, SeHCAT (selenium-75-homocholic acid taurine) is not
standardized.
Quality of Life After Crohn Disease Surgery
The quality of life (QoL) is in general good after CD surgery
at pediatric age. Piekkala et al (37) found comparable QoL between
the patients and controls, but when patients had school or work
absences the QoL decreased. The type of surgery or the number of
complications did not appear to have an effect on QoL. Two studies
from the same center, performed on limited number of patients
(n¼ 5 in both studies) reported that stoma formation was associated
with restricted sport activities in children (129,130). On the other
hand, Piekkala found no effect of permanent stoma on QoL in
children compared to adult patients with a stoma who scored lower
for general health and physical activity compared to controls
(37,131).
Intestinal Obstruction
One of the late complications of surgery in CD patients is
intestinal obstruction. Pediatric data showed that the incidence of
bowel obstruction caused by adhesions or anastomotic stricture
varied from 1.2% to 9.1% for the first 12 to 24 months after the
surgery (29,31,53,132). Only 1 study reported bowel obstruction
due to adhesions in 12/36 (33.3%) and anastomotic stenosis/
stricture in 9/36 (25%) of patients with a median follow-up of
10 years (37).
Strong evidence does not exist linking specific surgically
related factors to the postoperative development of intestinal
obstruction. A pediatric study found a higher risk to re-stricture
following strictureplasty compared with resection (133); however,
data are not uniform (50). Another proposed risk factor is end-to-
end anastomosis, but a meta-analysis of adult data found that end-
to-end anastomosis is not associated with an increased risk for
obstruction (134,135). One RCT in adults found that open surgery is
more likely to cause obstruction compared with laparoscopic
procedure, whereas another found no advantages of laparoscopic
procedure over open surgery (136,137).SPGHAN. All rights reserved.
www.jpgn.org
TABLE 2. Endoscopic recurrence after surgery
Endoscopic score Definition
i0 No lesions
i1 5 aphtous lesions
i2 >5 aphtous lesions with normal mucosa between
the lesions, or skip areas of larger lesions, or
lesions confined to the ileocolic anastomosis
i3 Diffuse aphtous ileitis with diffusely inflamed
mucosa
i4 Diffuse inflammation with already larger ulcers,
nodules, and/or narrowing
Rutgeerts score (151).
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Studies in adults found that the cumulative incidence for
intestinal failure in CD is 1% after 5 years and 4.5% to 6.1% after
15 years from initial surgery (138,139). Identified risk factors
include penetrating disease type, remaining small intestine of
<200 cm, ostomy creation and colectomy (140). Based on these
observations, surgical treatment should preserve bowel length as
much as possible by using bowel sparing techniques, including
strictureplasty and limiting removal of the bowel to those areas
associated with the symptoms (141,142).
Fertility
Abdominal surgery in patients with severe inflammation may
be associated with impaired fertility, whereas in less ill patients
fertility is preserved as recently shown in a large cohort of women
undergoing surgery for appendicitis (143). There are no studies on
pediatric CD.
SCHEDULE FOR FOLLOW-UP AFTER SURGERY
Statement 16. Postoperative medical treatment should be
based on ileocolonoscopy assessment and not solely on
symptoms or serum inflammatory markers. Repeated
fecal biomarkers testing may aid in deciding on the timing
of endoscopy. (Agreement 100%)
Practice points:1. P
t
wwostoperative endoscopic evaluation should be performed at 6
o 9 months after surgery (144,145).
Local recurrence limited to the anastomotic site (Rutgeerts i1),2.
however, is common but does not indicate need for changing
therapy in asymptomatic patients.
Fecal calprotectin is superior to C-reactive protein (CRP) and3.
clinical disease activity indices in monitoring disease recur-
rence. It is advisable to test calprotectin level repeatedly during
the follow-up to detect early asymptomatic recurrence. The
scheme for most effective follow-up is not established but
testing at least 2 to 3 times per year is advisable.
Magnetic resonance enterography, abdominal ultrasound, and4.
wireless capsule endoscopy can detect disease recurrence but
are not a substitute for endoscopy.Predictors of Early Recurrence
There are no pediatric studies identifying predictors of early
recurrence after surgical resection in CD but the risk is high
(27,35,37,38). In adults, there are recognized as risk factors for
recurrence, such as smoking, penetrating disease, perianal disease,
presence of granuloma in the resected segments, submucosal
plexitis, or presence of extraintestinal manifestations (146).
Although clinical recurrence occurs in 30% during the first
year after resection, approximately 80% show endoscopic recurrence
that precedes clinical symptoms (147). Therefore, endoscopic recur-
rence is the strongest predictor of disease progression (148–151).
Rutgeerts index is the most widely used measure to assess endoscopic
lesions and has a strong predictive validity in adults (Table 2)
(151,152). Rutgeerts score i2 has higher risk of clinical recurrence
at 4 years compared with score<i2 (100% vs 9%, respectively) (151).
Monitoring to detect recurrence is important. Because pub-
lications dealing with this issue are almost all based on adult
patients, pediatric recommendations have to be extrapolated. The Copyright © ESPGHAN and NA
w.jpgn.orgrecently published Australian randomized postoperative Crohn endo-
scopic recurrence trial (POCER) study evaluated the efficacy of
endoscopically tailored treatment (153). A cohort of 174 adult CD
patients was included and all received medical prophylaxis starting
immediately after surgery. After randomization (2:1) further step-up
in treatment was based upon findings at ileocolonoscopy at 6 months
(endoscopy group) or clinical symptoms (control group). Ileocolono-
scopy performed 18 months after surgery showed recurrence in 49%
in the endoscopy group versus 67% (P¼ 0.03) in the control group.
Therefore, ileocolonoscopy performed 6 months after resection is
recommended to monitor for postoperative recurrence (154). There is
poor correlation between postoperative endoscopic recurrence and
clinical symptoms, Crohn’s disease activity index (CDAI) or blood
inflammatory markers such as CRP (12,27,147,155).
Fecal calprotectin may be used to screen patients who require
colonoscopy for detecting mucosal recurrence and may be helpful
in the timing of endoscopy (156,157). This is supported by data
from the POCER study, which shows that the level of calprotectin
correlates well with endoscopic recurrence but not with CRP or
CDAI (153,158,159). Level of calprotectin >100 mg/g indicated
endoscopic recurrence with a sensitivity 0.89 and negative pre-
dictive value 0.91. This means that colonoscopy could have been
avoided in 47% of patients. Another adult study reported accordingly
that the best cutoff point for calprotectin was 100 mg/g to distinguish
between endoscopic remission and recurrence, with a sensitivity 0.95
and negative predictive value 0.93 (160). Such levels are, however,
close to normal values, and therefore the level of calprotectin that
practically should lead to endoscopy remains to be determined. There
are no pediatric data yet on the strategy of follow-up after surgery. A
small pediatric study reported that when compared with first
postoperative fecal calprotectin, the concentration of calprotectin
increased significantly more in patients with either endoscopic or
histological recurrence versus no recurrence. The best cutoffs in
pediatric patients were as follows: calprotectin>139 mg/g or increase
of 79 mg/g compared with first postoperative value were suggestive of
endoscopic recurrence (Rutgeerts score i2–i4), while calprotectin
>101 mg/g or increase of 21 mg/g indicated histological recurrence
(161). It must be, however, noted that exact levels of calprotectin may
differ with specific brands; therefore, reference values must be
determined locally according to the method used.
Abdominal US and CT can also be used for detection of
disease recurrence, but because of radiation CT should be avoided
in children, if possible (162). One study found magnetic resonance
enterography to have a similar value in predicting postoperative
recurrence as ileocolonoscopy (163). A number of small studies
with conflicting data show that wireless capsule endoscopy may be
used in detecting mucosal lesions post-surgery in selected patients
(156–158). Presently none of these studies have, however, proven
to be superior to ileocolonoscopy for disease sited within the reachSPGHAN. All rights reserved.
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Amil-Dias et al JPGN  Volume 64, Number 5, May 2017of ileocolonoscopy. In patients with lesions of the small bowel then
magnetic resonance enterography is more appropriate.
PREVENTION OF RECURRENCE
The risk of recurrence depends on several factors. Patients
with extensive disease, short disease duration from diagnosis to
surgery, recurrent surgery, long resected segment, surgery for
fistulizing disease, disease complications, impaired growth, pub-
ertal delay, perianal disease, or smoking habits may be categorized
as having high risk and therefore need a more active follow-up.
Thiopurines
Statement 17. 1. Thiopurines may be used for preventing
postoperative recurrence when a child has a moderate risk
of CD recurrence. (Agreement 100%)
Statement 18. 2. When thiopurines have failed preopera-




82hiopurines should be considered after surgery in thiopurine-
aı̈ve patients with extensive disease or risk factors of relapse.
When preoperatively adequately treated with thiopurines and
disease activity results in surgery, the efficacy of using
thiopurines in preventing recurrence is uncertain as most of
the reported data of the postoperative efficacy come from
patients previously treatement naı̈ve. In patients pretreated with
thiopurines, relapse prevention with methotrexate may be an
option, but there are no specific data available.Thiopurines (azathioprine [AZA] and 6-mercaptopurine
[6MP]) have a well-established role in maintaining remission in
CD. Their efficacy in preventing postoperative recurrence is debated
and all data come from adult studies (164–166). The ECCO 2010
guideline advocates their use postoperatively in patients with ‘‘high-
risk’’ factors (13). Thiopurines were superior over 5-ASA in pre-
venting any endoscopic recurrence at 12 months but not severe
recurrence, and not clinical recurrence at 12 or 24 months (167–
170). Combining the only studies with a placebo arm, however,
demonstrated that the use of thiopurine reduced clinical and severe
endoscopic recurrence at 12 months (169,171). The superiority of
thiopurine over 5-ASA was shown in a third meta-analysis, although
thiopurines were associated with more adverse events (172,173). In
the RCTs, most patients randomized to receive AZA/6-MP were
thiopurine-naı̈ve (previous thiopurine exposure in 7% in the
D’Haens’ study, 8.5% in the Ardizzone study, not specified in the
Hanauer study) (169,171,174). There is no evidence-based data on the
use of MTX in preventing postoperative recurrence in pediatric CD.
Biologics
Statement 19. 1. Treatment with anti-TNFa is recom-
mended when a CD patient has a high risk of postoperative
recurrence or has widespread disease. (Agreement 100%)
Statement 20. 2. When a patient experiences endoscopic
recurrence after intestinal resection despite optimal thio-
purine treatment, the therapy should be escalated to anti-
TNFa medication. (Agreement 100%) Copyright © ESPGHAN and NA
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Practice points:
1. Anti-TNFa treatment may be used postoperatively if the patient
has been a primary responder, did not develop anti-TNFSPantibodies and also in those with widespread disease, that is,
active disease beyond the resected site.
Those with reintroduction of anti-TNFa after an interval of2.
>12 weeks need careful monitoring for development of
antibody-associated loss of response.
Early endoscopic evaluation after surgery (suggested 6 months)3.
has been shown to be adequate to help decide when to introduce
anti-TNFa in patients without apparent disease after surgery
(153).Evidence for prophylactic anti-TNFa use in postoperative
recurrence is based on several small clinical trials in adults sum-
marized in Supplemental Digital Content, Table 1, http://links.lww.-
com/MPG/A936. The most recent RCT study, POCER study,
concluded that selective immune suppression, adjusted for early
recurrence, rather than routine use, leads to disease control in most
patients (153).
Most of the adult studies cited did not include patients
previously treated with anti-TNFa. In the randomized, double-
blinded, placebo-controlled study on anti-TNFa in postoperative
CD, there were only 8 patients who had received prior IFX (30% in
the IFX group) within 6 months of surgery (number of infusions 1–
4) (155). Patients with fibrostenosis or penetrating disease were not
considered true primary nonresponders, but rather had developed
complications that required surgery. In the POCER study no more
than one-third of the studied patients had previously received anti-
TNFa (21% and 29% of the active care and the standard care
groups, respectively) (153). Therefore, there is insufficient data to
establish if anti-TNFa agents are less effective in preventing
recurrence if prescribed for the patient who failed treatment before
the surgery as compared to the anti-TNFa-naı̈ve patient. Also, the
presence of drug antibodies underlying loss of response is less
reported. The use of IFX reduced the rate of endoscopic but not
clinical recurrence (175).
One study reported benefit from lower doses of anti-TNFa
(IFX 3 mg/kg) to maintain remission but trough levels were not





he evidence is weak to support the use of the following post-
perative prevention medications: 5-ASA/sulfasalazine, bude-
sonide, antibiotics, and probiotics.There are no pediatric studies evaluating these medications.
Trials of mesalazine therapy (3–4 g/day) showed a significant
reduction of risk of clinical (relative risk [RR] 0.76, 95% CI
0.62–0.94) and severe endoscopic recurrence (RR 0.50, 95% CI
0.38–0.92) in adults but the number needed to treat for these
outcomes was high (12 and 7, respectively) (169,177–181). Also,
nitroimidazole antibiotics (eg, metronidazole) have been used to
prevent relapse, but they may not produce added benefit when used
as concomitant therapy with AZA (182). Adverse effects may limit
long-term use in children. A Cochrane review, which evaluated 2
adult trials, concluded that the risk of clinical and endoscopic
recurrence was reduced with nitroimidazole antibiotics compared
with placebo (RR 0.23, 95% 0.09–0.57, number needed to treat¼ 4
and RR 0.44, 95% CI 0.26–0.74, number needed to treat¼ 4)GHAN. All rights reserved.
www.jpgn.org
JPGN  Volume 64, Number 5, May 2017 Surgical Management of Crohn Disease in Children(164,183,184). In 1 trial metronidazole was administered for 3
months and in the other, ornidazole for 1 year. Results for cipro-
floxacin (500 mg bid for 6 months vs placebo) have been disap-
pointing in a recent pilot RCT (185). Budesonide and probiotics are
ineffective in relapse prevention (186–191).
Partial EN may be an effective treatment option to prevent
postoperative recurrence based on a nonrandomized prospective
study in 40 adult CD patients with ileal or ileocolonic resection
(192). In the EN group, 1 of 20 patients developed clinical recur-
rence compared with 7 of 20 in the non-EN group during 1-year
follow-up (endoscopic recurrence rates were 30% vs 70%, respect-
ively). EN consisted of nocturnal infusion of elemental diet (via
nasogastric tube) along a low-fat diet during the day for 12 months,
compared with no nutritional intervention (non-EN group). All of
the patients received 5-ASA medication. The treatment acceptabil-
ity was low (50%). The beneficial effect of EN in preventing
postoperative recurrence following resection was further supported
by a 5-year follow-up study (193). Another nonrandomized study
from Japan suggested a benefit in preventing postoperative recur-
rence from taking >50% of calories in the form of EN (194). No
pediatric trial to date has evaluated the potential or efficacy of
postoperative EN in preventing recurrence.
HOW TO CHOOSE THE TYPE OF
POSTOPERATIVE MAINTENANCE MEDICATION
Selecting the most appropriate therapeutic intervention for
prevention of postoperative recurrence of CD remains a challenging
clinical problem, especially in children in whom there is a lack of
Level 1 evidence. Although the majority of patients with CD will
eventually require surgery, most of those who are left untreated
postoperatively will develop disease recurrence within a few years
and many will need reoperation within 10 years (37,38,195). Given
the fact that children who undergo resection have a lifelong risk for
repeated resections and are at risk to develop short bowel syndrome,
the issue of preventing recurrence is of the greatest importance. The
suggested algorithm is presented in Figure 1.
Practice points:1. L
s
wwow-risk patients may be given no prophylaxis medication after
urgery or only 5-ASA if signs of colonic involvement.
Maintenance enteral nutrition may also be considered
(196,197).
In high-risk patients (extensive disease, short disease duration2.
from diagnosis to surgery, recurrent surgery, long resected
segment, surgery for fistulizing disease, disease complications,
perianal disease, smoking) anti-TNFa is the most effective
therapy, even in patients who were treated before surgery.
Ileocolonoscopy is recommended 6 to 9 months after surgery3.
with treatment step-up if Rutgeerts score is  i2)
Fecal calprotectin may be evaluated at regular intervals, for4.
example, every 3 to 6 months, with further endoscopy in case of
significant increase. Most published studies suggest best cutoff
level of fecal calprotectin as 100 mg/g for predicting endoscopic
recurrence but lower values of 60 or 75 mg/g have also been
suggested (198,199).The role of endoscopy-guided treatment to modify clinical
outcome has been evaluated in several adult retrospective studies
with conflicting results (158,200,201). A prospective study (174
patients enrolled) revealed that at 18 months after surgery recur-
rence occurred in 49% versus 67% (randomization 2:1 to either
endoscopy tailored treatment at 6 months postoperatively or control
group (P¼ 0.028); patients in both groups received prophylaxis
starting immediately after surgery (153). A small Japanese Copyright © ESPGHAN and NA
w.jpgn.orgprospective study with a 5-year follow-up period has revealed
comparable results (193). Alike in adults, a constant rise in fecal
calprotectin is suggestive of disease recurrence in children (161).
PERIANAL DISEASE
Perianal CD is a complex condition that is frequently refrac-
tory to treatment and needs a combined medical and surgical
approach. In adult CD, up to 54% of patients present with perianal
complications, perianal fistulas develop in 20% and recurrence
occurs in approximately 30% of patients (202,203). The majority
of patients with perianal fistulas have colonic disease involving the
rectum (204). Perianal manifestations including fissures and skin tags
are present in 13% to 62% of children with CD (205). Perianal fistulas
are present in 10% to 15% of the time at diagnosis (206–208).
Diagnostic Approach
Various fistula classifications have been proposed either
relating fistulas to the ano-rectal ring (high or low) or more
precisely as described by Parks, using the external sphincter as
the reference point (29). For clinical practice, classification into
simple (superficial involvement of the external sphincter by single
fistula tract without rectal inflammation or abscess) and complex
(deep or extensive involvement of the sphincter musculature by
fistula tract or associated rectal inflammation, abscess or stenosis)
perianal fistula is more relevant (207,210,211). For the management
of perianal fistulizing CD it is essential locate the fistula origin,
establish the anatomical course of the fistula tract and exclude or
identify the presence of associated rectal inflammation or abscess
(207,211,212).
Statement 21. Pelvic MRI and evaluation under anesthesia
by a surgeon with experience in pediatric anorectal dis-
ease should be among the initial procedures in evaluating
a child with suspected complex perianal CD. (Agreement
100%)
Statement 22. Disease extension should be re-evaluated by
ileocolonscopy in all patients with complex perinanal
disease manifesting after primary diagnostic investi-
gations of CD. Concomitant intestinal lesions (inflam-
mation, stenosis) have both prognostic and therapeutic
relevance. (Agreement 100%)
When the child has perianal pain an abscess is almost always
present. In such situations prompt evaluation under anesthesia,
including drainage, is the procedure of choice to minimize damage
to the sphincter (212–214). Nevertheless, pelvic MRI has an
accuracy of 76% to 100% for fistulae in studies performed in adults
and it has become an essential tool as well for children providing
important information for the surgeon about the tract of the fistula
and identifying an abscess (203,214–219). When pain is not
present, most children will tolerate a gentle digital rectal examin-
ation to identify a stricture or fluctuance. The most common
approach to evaluate perianal CD for children involves an external
and rectal examination followed by MRI imaging and examination
under anesthesia by an experienced surgeon (212). Fistulography is
rarely needed for evaluation of the fistula tract. Endoscopic ultra-
sound has also been used to diagnose and guide management of
perianal disease with satisfactory result (220). Disease extension
should be re-evaluated by ileocolonoscopy in all patients with
complex perianal disease that develops after primary diagnostic
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Colonoscopy at 9−12 months
postsurgery











Repeat calprotection every 3−6
months and  colonoscopy when
elevated
IMM or anti-TNF according to
the severity of relapse (***)
FIGURE 1. Therapeutic algorithm for preventing postoperative recurrence in pediatric Crohn disease. (

) High-risk factors are growth failure,
delayed puberty, short duration from diagnosis to surgery, extensive resection (>40 cm), penetrating behavior, active disease beyond resected
site. (

) Fecal markers cutoff according to local reference value (see text, Section 10, practice point 4). (

) Decision of the given therapy
according to the severity of relapse and disease history. IMM¼ immunomodulator; MEN¼maintenance enteral nutrition.
Amil-Dias et al JPGN  Volume 64, Number 5, May 2017A less common condition described as severely destructive
form, separate to the more commonly recognized perianal disease is
reported rarely but is a real treatment challenge. Markowitz et al
(221) were the first to report in 1995 such a severe and mutilating
form and named it highly destructive perianal disease (HDPD).
They identified 67 of 230 patients (29%) (children and adolescents) Copyright © ESPGHAN and NA
828with perianal disease of which only 6 (2.6% of total children) were
described with HDPD. Since then there have been a few other case
reports highlighting the severity of the condition and difficulty of
treatment (222–225). It is characterized by visualization of deep
perianal ulceration and tissue destruction associated with copious
exudate with involvement of perineum and surrounding areas.SPGHAN. All rights reserved.
www.jpgn.org
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therapies including hyperbaric oxygen even with the advent of
biologics and often diverting the fecal stream via an ostomy to
promote perianal healing is the only effective form of management.
Successful skin grafting of the perianal ulceration following fecal
stream diversion has been described (223,225).
Treatment of Perianal Fistulae
Statement 23. Treatment of perianal CD should be based
on combination of surgery, antibiotics and biologics.
(Agreement 100%)
Statement 24. Presence of perianal abscess should be ruled
out early and when detected drainage should be discussed
with the surgeon. (Agreement 100%)
Statement 25. Placement of noncutting seton should be
considered in all complex fistula tracts, especially in those
with recurrent abscesses. (Agreement 100%)
Practice points:1. I
b
wwwn asymptomatic simple perianal fistulae no actions are needed
ut careful monitoring is recommended.
Symptomatic simple fistulae should be treated either with2.
placement of noncutting seton or in superficial cases
with fistulotomy.
Uncomplicated fissures may be treated with topical therapy.3.
4. Anti-TNFa agents should be used as primary medical
induction therapy for complex perianal CD in combination
with appropriate surgical intervention after effective abscess
drainage. After successful induction, anti-TNFa scheduled
maintenance is mandatory. Antibiotics may be used as second
line medical treatment until drainage from the abscess or
fistula has stopped. The evidence for the use of AZA-6MP
is weak.
Antibiotics, metronidazole (20–30 mg  kg1  day1) or5.
ciprofloxacin (10–20 mg  kg1  day1) are most widely used.
The timing of removal of setons depends on subsequent6.
therapy and treatment response.
Anti-TNFa should be continued for at least 1 year following7.
with abscess drainage.
In case of failure of IFX, ADA is recommended. In case of8.
failure to respond to available anti-TNFa agents and other
biologics with proven efficacy in CD, AZA/6-MP, metho-
trexate, or tacrolimus with antibiotics may be used.
The use of cutting setons may damage anal sphincter and9.
induce incontinence.
Fistulectomy and fistulotomy carry a risk of incontinence and10.
therefore should only be performed by expert surgeons (13).
Endorectal mucosal advanced flap is an option in the absence
of rectal disease and in case of a single fistula source that it is
easily identified.
Proctectomy (and permanent diversion) may be considered11.
when a patient has severe rectal and perianal disease.When a simple perianal fistula is symptomatic there is
consensus in adults to use antibiotics as the first therapeutic option,
azathioprine/6-mercaptopurine (AZA/6-MP) as the second option
and IFX as a third option. Combined medical and surgical approach
is favored (212).
There is lack of controlled evidence on the efficacy of
antibiotics that are the first-line therapy especially in simple fistula
in children and adults (209,211,212). There are no controlled trials Copyright © ESPGHAN and NA
.jpgn.orgassessing the effect of AZA/6-MP on the closure of perianal fistulae
as primary endpoint (204,226,227). Small uncontrolled series on
efficacy of intravenous cyclosporine A and oral tacrolimus have
been reported (228,229).
In adults, IFX was the first agent shown to be effective in an
RCT for inducing closure of perianal fistulae and maintaining
response over 1 year (complete closure in 55% vs 13% in the
placebo group) (230). In another trial, randomized controlled trial to
assess the efficacy and safety of repeated infusions of infliximab in
patients who improved after an initial infusion of infliximab
(ACCENT) II, complete closure was seen in 36% at week 54.
Comparable results with ADA (Crohn trial of the fully human
antibody adalimumab for remission maintenance [CHARM]) have
been observed in adults (231,232). Results on the use of ADA
following IFX failure or intolerance are conflicting (233,234). In
fistulizing disease, maintenance on IFX reduced hospitalization and
surgery (235,236).
In pediatrics the post-hoc analysis of 22 patients with peri-
anal CD of REACH study, response rates were 41% at week 2 and
72% at week 54 (237). In another study, long-term clinical response
to IFX was observed in 9 of 16 patients with refractory CD and
draining fistulae (238). Top down strategy compared with a step up
approach in a small group of pediatric patients showed better results
(3/6 in the step up group compared with 12/12 completely closed in
the top down group) at 1 year (239). As of yet there are no published
studies on the use of ADA in this context.
The combination of IFX and surgery with seton placement
gives better results, longer effect duration and lower rate of
recurrence to either treatment alone most likely related to better
drainage of the abscess and fistulae (240–243). One strategy is to
place seton before the start of therapy with IFX. Loose noncutting
setons are used because a cutting seton may cause damage to the
anal sphincter resulting in incontinence (207). In a recent retro-
spective study in 13 adolescent patients with complex perianal
fistulae treated with seton placement and then IFX, >90%
responded. Fistula response 8 weeks was complete in 77% and
partial in 15%. Fistula recurred in 3/13 (23%) patients, 2 on
biological therapy and 1 after discontinuation of treatment (244).
The loss of response to biological therapy was associated with
detectable drug antibodies.
Anti-TNFa medication may be used as a first choice of
treatment for complex perianal CD following radical surgery of
‘‘Cone-like’’ fistulectomy of each fistula tract with sparing of the
sphincter (211). In the recent ECCO/ESPGHAN pediatric guide-
lines for medical management of CD anti-TNFa therapy is recom-
mended as primary induction and maintenance therapy for children
with active perianal fistulizing disease in combination with appro-
priate surgical intervention (11). The tract may persist as assessed
by MRI and drainage usually recurs if treatment is stopped (212).
Surgical treatment always is considered indicated for complex
perianal CD. A perianal abscess should always be drained.
There is uncontrolled evidence that local injection of IFX
close to the fistula tract may be beneficial in patients not responding
to or intolerant of intravenous IFX (11,245). Also, intralesional
administration of mesenchymal stem cells has been reported as a
promising treatment option in complex perianal fistula in adults
(246).
A diverting ostomy or proctectomy may be necessary for
severe disease refractory to medical therapy. In such patients the
risk of the ostomy becoming permanent is significant (207). Rectal
stenosis or strictures are relatively rare findings in children with CD
and most commonly located at the dentate line. They may respond to
repeated anal dilatation under anesthesia. A refractory short stricture
may be amenable for stricturoplasty, whereas more extensive stric-
tures may require fecal diversion with or without proctectomy.SPGHAN. All rights reserved.
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The most common fistulae in CD are enteroenteric. Surgical
management typically involves resection of the diseased segment of
bowel and closure of the connection with uninvolved intestine.
Similarly, enterovesical fistula are managed by resection of the
diseased segment and primary closure of the bladder.
Enterocutaneous Fistulae
Management of enterocutanoeus fistulae reported in children
with CD is a complex challenge (36). IFX had modest effect on 25
patients out of 282 with rectovaginal fistulae (236). Early re-
operation to close a fistula tract is often associated with recurrence
or further complications. Optimizing the nutritional status is of
importance in such situations (212).
Enterogynecalogical Fistulae
In low anal-introital asymptomatic fistula surgery may not be
necessary. In patients with symptomatic fistula surgery may be
necessary including diverting ostomy.
Rectovaginal fistulae have been rarely reported in children
(221,247). Surgery for such a condition should be tailored indivi-
dually. Resection of the diseased gut segment is usually necessary
when small bowel or sigmoid-gynecological fistulae are present
(212). Rectovaginal fistulae not responding to conservative treat-
ment should be treated surgically with an advancement flap and
diverting-ostomy when necessary because of the presence of unac-
ceptable symptoms (212,248–251). In recurrent fistulizing disease
gracilis muscle interposition has been successfully reported
(252,253).
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